Search

Solid polymer electrolytes (SPEs) that can offer flexible processability, highly tunable chemical functionality, and cost effectiveness are regarded as attractive alternatives for liquid electrolytes (LE) to address their safety and energy density limitations. However, it remains a great challenge for SPEs to stabilize Li+ deposition at the electrolyte–electrode interface and impede lithium dendrite proliferation compared with LE‐based systems. Herein, a design of solid‐state fluorinated bifunctional SPE (FB‐SPE) that covalently tethers fluorinated chains with polyether‐based segments is proposed and synthesized via photo‐controlled radical polymerization (photo‐CRP). In contrast to the conventional non‐fluorinated polyether‐derived SPEs, FB‐SPE is able to provide conducting Li+ transport pathways up to ≈5.0 V, while simultaneously forming a LiF interaction that can enhance Li anode compatibility and prevent Li dendrites growth. As a result, the FB‐SPE exhibits outstanding cycling stability in Li||Li symmetrical cells of over 1500 operating hours at as high current density as 0.2 mA cm−2. A thin and uniform Li deposition layer and LiF‐rich SEI at the surface of Li anode are found, and stable cycling with average coulombic efficiencies of 99% is demonstrated in Li||LFP and Li||NCM all‐solid‐state batteries based on such bifunctional fluorinated SPEs. The interesting fluorine effect and effective self‐suppression of lithium dendrites will inform rational molecular design of novel electrolytes and practical development of all‐solid‐state Li metal batteries. [ABSTRACT FROM AUTHOR]

Mycoplasma pneumoniae is a leading cause of community-acquired respiratory infections. Infantile Feire Kechuan Oral Solution (IFKOS) is effective for treatment of M. pneumoniae infection. The aim of this study was to explore the potential mechanism of IFKOS against M. pneumoniae infection in basal epithelial human lung adenocarcinoma A549 cells. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to determine the effects of IFKOS on the viability of A549 cells infected with M. pneumoniae. Optical microscopy was used to observe cell morphology and a Muse cell analyzer was used to assess apoptosis and the cell cycle phase. Enzyme-linked immunosorbent assays were employed to assess the expression levels of interleukin (IL)-4, IL-6, IL-8, IL-17, tumor necrosis factor (TNF)-α, interferon (IFN)-α, and IFN-γ. Under certain conditions, M. pneumoniae infection reduced the viability and inhibited the proliferation of A549 cells, promoted early apoptosis, and arrested cells in the G0/G1 phase, thus shortening the S and G2/M phases (all p < 0.05). M. pneumoniae also upregulated expression of IL-8 and TNF-α and downregulated that of IL-6 (p < 0.05), which switched the immune balance of Th1/Th2 to Th1 cells. IFKOS (5.531 mg/mL) improved the viability and proliferation of M. pneumoniae -infected A549 cells, mitigated early apoptosis, and reversed cell cycle arrest in the G0/G1 phase, thereby extending the S and G2/M phases (all, p < 0.05). IFKOS downregulated expression of IL-8 and TNF-α and upregulated that of IL-6 (p < 0.01), thereby reversing the immune imbalance of Th1/Th2. Secretion of IL-4, IL-17, IFN-α, and IFN-γ was not observed. IFKOS played a protective role in the regulation of cell viability, apoptosis, the cell cycle, and Th1/Th2 immune imbalance induced by M. pneumoniae infection and conveyed an anti-inflammatory effect in A549 cells. • Mycoplasma pneumoniae is an important pathogen of community-acquired pneumonia in children. • Infantile Feire Kechuan Oral Solution (IFKOS) is effective for treatment of Mycoplasma pneumoniae pneumonia. • M. pneumoniae reduced the viability of A549 cells, promoted apoptosis, arrested cell cycle, and disordered cytokines. • IFKOS improved the viability of M. pneumoniae -infected A549 cells, mitigated apoptosis, reversed cell cycle arrest, and regulated cytokines. [ABSTRACT FROM AUTHOR]